Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Basic) (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EPS (Basic) for 15 consecutive years, with $1.53 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 48.54% year-over-year to $1.53, compared with a TTM value of $4.81 through Dec 2025, up 42.31%, and an annual FY2025 reading of $4.81, up 41.47% over the prior year.
  • EPS (Basic) was $1.53 for Q4 2025 at Neurocrine Biosciences, down from $2.11 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.11 in Q3 2025 and bottomed at -$0.79 in Q1 2023.
  • Average EPS (Basic) over 4 years is $0.78, with a median of $0.85 recorded in 2023.
  • The sharpest move saw EPS (Basic) soared 154.43% in 2024, then tumbled 81.4% in 2025.
  • Year by year, EPS (Basic) stood at $0.24 in 2021, then soared by 529.17% to $1.51 in 2023, then tumbled by 31.79% to $1.03 in 2024, then surged by 48.54% to $1.53 in 2025.
  • Business Quant data shows EPS (Basic) for NBIX at $1.53 in Q4 2025, $2.11 in Q3 2025, and $1.09 in Q2 2025.